Dipyridamole

ATC code

B01AC07

Therapeutic class

Platelet aggregation inhibitor · Platelet aggregation inhibitor, excluding heparin

Forms

oral tablet

Brand names

Persantin (ES) · Persantine (US) · Aggrenox (US)

Overall confidence

medium

Regulatory sources consulted

Prophylaxis of thromboembolism in patients with prosthetic heart valves, in combination with oral anticoagulants.
Treatment of chronic stable angina pectoris.

Hypersensitivity to dipyridamole or excipients.
Unstable angina, recent myocardial infarction, subvalvular aortic stenosis, hypotension or hemodynamic instability.

Major warning · Vasodilatory properties: may cause hypotension. Use with caution in severe coronary artery disease (risk of 'coronary steal'). — AEMPS CIMA
May worsen myasthenia gravis by counteracting the effect of cholinesterase inhibitors. — AEMPS CIMA

HighAdenosineC01EB10
Mechanism: Dipyridamole inhibits the cellular uptake of adenosine, increasing its plasma concentrations and cardiovascular effects.
Recommendation: If concomitant use is unavoidable, consider a substantial reduction in the adenosine dose and monitor closely.
AEMPS CIMA
ModerateCholinesterase inhibitorsN06DA
Mechanism: Dipyridamole has weak anticholinesterase activity that may counteract the effect of cholinesterase inhibitors, potentially worsening myasthenia gravis.
Recommendation: Monitor the effectiveness of myasthenia gravis treatment. A dose adjustment of the cholinesterase inhibitor may be necessary.
AEMPS CIMA

headache · dizziness · nausea · diarrhea · myalgia · hypotension · hot flushes

thrombocytopenia · worsening of angina · hypersensitivity reactions

Safety in pregnancy has not been established; use only if strictly necessary. It is excreted in breast milk; use with caution during lactation.